Larger, more ethnically diverse cohorts (99% of the current cohort was white) are needed to confirm the hypothesis that antimalarials exert some favorable action against some of the predisposing factors in patients with SLE, according to the authors. Such confirmation “would reinforce the recommendation of universal use of hydroxychloroquine in all patients with SLE,” they concluded.